Patents Assigned to ICURE Pharmaceutical Inc.
  • Patent number: 11382868
    Abstract: The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.
    Type: Grant
    Filed: February 1, 2017
    Date of Patent: July 12, 2022
    Assignee: ICURE PHARMACEUTICAL INC.
    Inventors: Young Kweon Choi, Yong Ho Oh, Seong Su Kim, Hwan Ki Ho, Song Mi Han, Myung Jin Kim
  • Patent number: 10888533
    Abstract: The present invention relates to a transdermal composition for dementia treatment containing donepezil as an active ingredient. The transdermal composition according to the present invention contains highly concentrated donepezil in a hydrophobic matrix, can continuously release the drug for a long time by having excellent long-term adhesion to the skin, and further exhibits consistently effective therapeutic effects over a long period of time by having a significantly improved skin penetration rate in comparison with conventional donepezil patches.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: January 12, 2021
    Assignee: ICURE PHARMACEUTICAL INC.
    Inventors: Young Kweon Choi, Dong Hyun Hong, Seong Soo Kim
  • Publication number: 20190046463
    Abstract: The present invention relates to a UV-curable hydrogel resin for transdermal administration, a hydrogel prepared using the UV-curable hydrogel resin, and a cataplasm prepared using the UV-curable hydrogel resin. More particularly, the present invention relates to a hydrogel resin with an optimal composition and composition ratio which allows increase in a water content of a hydrogel applied as a drug layer of a cataplasm, skin irritation mitigation, and crosslinking degree adjustment for adhesion control and is capable of controlling drug releasing property and transdermal absorbability, a hydrogel prepared by UV-hardening the hydrogel resin, and a cataplasm including the hydrogel.
    Type: Application
    Filed: February 1, 2017
    Publication date: February 14, 2019
    Applicant: ICURE PHARMACEUTICAL INC.
    Inventors: Young Kweon CHOI, Yong Ho OH, Seong Su KIM, Hwan Ki HO, Song Mi HAN, Myung Jin KIM
  • Publication number: 20130165875
    Abstract: The present, invention relates to a transdermal absorption preparation. The transdermal absorption preparation of the present invention comprises a drug-containing adhesive layer, a drug-protective layer and a release layer, wherein the drug-containing adhesive layer contains ropinirole or a salt thereof, rubber, an adhesion-imparting resin, an antioxidant, and a transdermal absorption promoter. Also, the present invention provides a transdermal absorption preparation comprising a drug-containing adhesive layer, a drug-protective layer, and a release layer, wherein the drug-containing adhesive layer contains ropinirole or a salt thereof, acrylic rubber, an anti-crystallisation agent, and a transdermal absorption promoter. When the transdermal absorption preparation of the present invention is used for the treatment of Parkinson's disease or restless leg syndrome, no side effect due to an increase in the initial drug concentration in blood occurs and the skin penetration effect of the drug is excellent.
    Type: Application
    Filed: April 21, 2011
    Publication date: June 27, 2013
    Applicant: ICURE Pharmaceutical Inc.
    Inventors: Young Kweon Choi, Jung Ju Kim, Seong Su Kim, Jung Sik Lee, Seong Min Park